New study tests easier treatment for blistering skin disease
NCT ID NCT02313870
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two ways to treat bullous pemphigoid, a severe blistering skin condition. One group used strong steroid creams for 9 months, while the other used steroids plus methotrexate for 4 weeks, then methotrexate alone for 8 months. The goal was to see if the combination treatment works as well as steroids alone, but is easier to manage. 322 adults took part in this phase 3 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Of Montpellier
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study reveals bone risks from common skin treatment
- Scientists probe hidden clot risks in autoimmune skin disorders
- One-Dose hope for blistering skin disease?
- New antibody treatment offers hope for rare blistering skin disease
- Researchers track blistering skin disease to pave way for better treatments
- New antibody shows promise for blistering skin disease